Robust initiation of corrective mechanisms is particularly important for diabetic patients since even without clinical HAAF glucagon release in response to hypoglycemia is nearly absent in type 1 and advanced type 2 diabetic patients (Bottini et al., 1997; Segel et al., 2002; Cryer, 2005; Israelian et al., 2006; Siafarikas et al., 2012; Oyer, 2013). The gene discussed is GCG; the disease is Hypoglycemia.